Molecule
Benzgalantamine is a prescription medicine indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. It is available as delayed-release tablets for oral use. MedsAcross supplies Benzgalantamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults
Source: US FDA prescribing information
Although the etiology of cognitive impairment in Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a neuropathological hallmark of Alzheimer's disease). ZUNVEYL is a prodrug of galantamine. Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase.
Source: US FDA prescribing information
The recommended starting dosage is 5 mg orally twice daily with or without food, increase to initial maintenance dosage of 10 mg twice daily after a minimum of 4 weeks based on clinical response and tolerability. Dosage may be increased to the maximum recommended dosage of 15 mg twice a day after a minimum of 4 weeks at 10 mg twice daily. Ensure adequate fluid intake during treatment. Swallow whole, do not split, crush or chew. May be taken with or without food. Should not be taken with alcohol. Hepatic impairment: Should not exceed 10 mg twice daily for moderate hepatic impairment, use in patients with severe hepatic impairment is not recommended. Renal impairment: Should not exceed 10 mg twice daily for creatinine clearance 9 to 59 mL/min, use in patients with creatinine clearance less than 9 mL/min is not recommended.
Source: US FDA prescribing information
ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredient in ZUNVEYL. Serious skin reactions have occurred. Known hypersensitivity to benzgalantamine, galantamine, or any inactive ingredients in ZUNVEYL
Source: US FDA prescribing information
Serious skin reactions: Discontinue at first appearance of skin rash. All patients should be considered at risk for adverse effects on cardiac conduction, including bradycardia and AV block, because of vagotonic effects on sinoatrial and atrioventricular nodes. Active or occult gastrointestinal bleeding: Monitor, especially those with an increased risk for developing ulcers. Cholinomimetics may cause bladder outflow obstruction. Monitor for respiratory adverse events in patients with a history of severe asthma or obstructive pulmonary disease.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in more detail elsewhere in the labeling: Serious Skin Reactions Cardiovascular Conditions Gastrointestinal Conditions Genitourinary Conditions Neurological Conditions Pulmonary Conditions The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.
Source: US FDA prescribing information
Potential to interfere with the activity of anticholinergic medications. Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists
Source: US FDA prescribing information
Store ZUNVEYL delayed-release tablets at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Benzgalantamine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zunveyl 10 mg delayed-release tabletOral | Alpha Cognition | US FDA | Available on request |
| Zunveyl 15 mg delayed-release tabletOral | Alpha Cognition | US FDA | Available on request |
| Zunveyl 5 mg delayed-release tabletOral | Alpha Cognition | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 26 July 2024 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Benzgalantamine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Benzgalantamine, including Zunveyl.
Yes. The US FDA first approved Benzgalantamine on 26 July 2024, according to Drugs@FDA.
No listed presentation of Benzgalantamine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.